Generic Drugs
HealthTrans reports generic utilization exceeds 60% in Q1 2006
Published in Medical Letter on the CDC and FDA, August 13th, 2006
A pharmacy benefit administrator (PBA), HealthTrans attributes this growth in part to successfully implementing plan benefit designs that advocate value-based formularies focusing on most cost-efficacious therapies, which in many cases fall to generic and even over the counter alternatives.
Stronger generic utilization typically provides for greater cost efficiencies in a transparent business model, because the drugs can be procured at much more aggressive rates and transparent relationships do not allow for mark-up pricing, so the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Breast Cancer
Rho GTPase regulator promotes breast cancer cell invasiveness - Food Safety
Epidemiologic data is used to measure impact of food safety control programs - Retinoic Acid
Pharmacokinetics of 13-cis-retinoic acid or all-trans-retinoic acid in rats is presented - Addiction Medicine
Concurrent use of alcohol and prescription drugs were studied in a university population - Addiction Medicine
Social influences on adolescent alcohol use are explored - Addiction Medicine
Social network participation aids retention in therapeutic communities - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
